EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Will the Institute for Clinical and Economic Review’s Shared Savings Approach Decrease Value-Based Prices Most for the Most Severe Diseases?

Jason Shafrin, Shanshan Wang, Khounish Sharma, Kathryn Spurrier, Robert J Nordyke

Value in Health · 2025

DOI: 10.1016/j.jval.2024.09.002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Value in Health, 2025. Verfasst von Jason Shafrin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Center for Healthcare Economics and Policy, FTI Consulting, Los Angeles, CA, USA. Electronic address: jason.shafrin@fticonsulting.com. Hauptthemen laut MEDLINE: Cost Savings, Cost-Benefit Analysis. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Pharmaceutical Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: To identify the types of disease most likely to be affected by the Institute for Clinical and Economic Review's (ICER) shared savings assumptions. METHODS: For diseases with treatments that were Food and Drug Administration approved between 2019 and 2023, annual direct and indirect economic burden and characteristics of each disease were extracted from peer-reviewed literature. ICER's shared savings methodology was applied 2 ways: 50/50 shared savings and $150 000 cost-offset cap. The primary outcome was the difference in eligible cost savings provided by a hypothetical disease cure under ICER's 2 shared savings methods. Characteristics of diseases most impacted by these 2 methods were evaluated descriptively. RESULTS: Food and Drug Administration approved 260 therapies for 89 unique diseases between 2019 and 2023. Shared savings reduced value of a hypothetical cure for hemophilia A most (50/50 method: -$367 670 per year; cap method: -$585 340 per year), followed by acute hepatic porphyria (50/50 method: -$333 948; cap method: -$517 896) and paroxysmal nocturnal hemoglobinuria (50/50 method: -$291 997; cap method: -$433 993). Compared with diseases with annual burdens

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cost SavingsCost-Benefit AnalysisHumansUnited StatesCost of IllnessModels, EconomicSeverity of Illness IndexQuality-Adjusted Life YearsUnited States Food and Drug Administration

Stichwörter der Autor:innen

ICERrare diseaseshared savings

Autor:innen und Institutionen

  • Center for Healthcare Economics and Policy, FTI Consulting, Los Angeles, CA, USA. Electronic address: jason.shafrin@fticonsulting.com.
  • Center for Healthcare Economics and Policy, FTI Consulting, Washington, DC, USA.
  • Center for Healthcare Economics and Policy, FTI Consulting, Los Angeles, CA, USA.
  • National Pharmaceutical Council, Washington, DC, USA.

Förderung

  • National Pharmaceutical Council

Zitieren

APA

Shafrin, J., Wang, S., Sharma, K., Spurrier, K., & Nordyke, R. J. (2025). Will the Institute for Clinical and Economic Review’s Shared Savings Approach Decrease Value-Based Prices Most for the Most Severe Diseases?. Value in Health. https://doi.org/10.1016/j.jval.2024.09.002

Vancouver

Shafrin J, Wang S, Sharma K, Spurrier K, Nordyke RJ. Will the Institute for Clinical and Economic Review’s Shared Savings Approach Decrease Value-Based Prices Most for the Most Severe Diseases?. Value in Health. 2025. doi:10.1016/j.jval.2024.09.002

BibTeX
@article{Shafrin2025,
  author = {Shafrin, Jason and Wang, Shanshan and Sharma, Khounish and Spurrier, Kathryn and Nordyke, Robert J},
  title = {Will the Institute for Clinical and Economic Review’s Shared Savings Approach Decrease Value-Based Prices Most for the Most Severe Diseases?},
  journal = {Value in Health},
  year = {2025},
  doi = {10.1016/j.jval.2024.09.002}
}
Kostenlos starten →